IFN␥ and Th2 cells producing IL-4, which has anti-inflammatory properties [Mosmann and Coffman, 1989] ), The Role of T and B Lymphocytes it is possible that nonspecific T cell directed immunoTwin and other genetic studies have demonstrated that therapy, such as those listed above, may be ineffective a major genetic contribution to disease predisposition because both pathogenic and protective T cell functions resides in the HLA-DR locus (Stasny, 1978) . More than would be downregulated. 80% of caucasian rheumatoid patients express DR1 or In view of the clear cut role of T cells in driving immune DR4 subtypes which share an epitope mapping to amino responses and in animal models of autoimmunity, inacids 70-74 of the DR␤ chain, in the polymorphic region cluding the collagen type II and other models of arthritis, lining the peptide binding groove (Gregersen et al., 1987) . As the only known function of DR is to present peptides to CD4ϩ T cells, this genetic association clearly implicates a role for T cells at some stage in the disease pathogenesis. However, it is not known which stage that may be. It could be in defining the T cell repertoire of antigen receptors or in the presentation of an inducing extrinsic antigen (e.g., pathogen) involved in the induction of the disease process. However, the most popular concept is that the pathogenic role for CD4ϩ T cells is in presentation of an autoantigen (Todd et al., 1988) . There is recent evidence that the genetically susceptible HLA-DR4 (e.g., DR0401) alleles bind different peptides in their peptide binding groove than the nonsusceptible (e.g., DR0402) alleles. Susceptible alleles bind a negatively charged amino acid at the p4 pocket of the binding groove, (Woulfe et al., 1995) . Mutation analysis revealed that position 71 of the DR␤ chain in particular correlates with the genetic linkage of RA (Hammer et al., 1995) . How this eventually it is on balance likely that T cells are involved both in disease induction and in disease maintenance. The most likely reason for their reduced function in active disease is the inhibitory cytokine environment, with augmented IL-10 and TGF␤ (Fava et al., 1989; Wahl, 1994; Katsikis et al., 1994) .
The role of B lymphocytes in RA has been extensively studied since the discovery that most patients have IgM autoantibodies termed rheumatoid factors (RF) which recognize the Fc region of IgG. However, RF are not present in all RA patients and are also present in other TNF␣ would also diminish the actions of many other IgM and the less frequent IgG RF differ from the germ pro-inflammatory mediators, and hence, that TNF␣ may line sequence, the latter extensively, suggesting the be a good therapeutic target. presence of an antigen driven process (Olee et al., 1992) .
Analogous studies have evaluated the expression of How RF factor contributes to the disease process is still anti-inflammatory cytokines in rheumatoid joints. TGF␤ not understood, but current concepts include a role in is abundant, both in latent and active form (Fava et al., facilitating antigen presentation. Immune complexes of 1989; Wahl, 1994) , as is IL-10 ( Katsikis et al., 1994) . In RF and IgG may contribute to disease activity by activatcontrast, IL-4 is not usually found, suggesting that the ing complement and stimulating cytokine synthesis.
T cells involved in RA joints are chiefly of the Th1 type. Augmented numbers of CD5ϩ B lymphocytes have been Cytokine inhibitors such as the IL-1 receptor antagonist detected in patients with RA (Plater-Zyberk et al., 1985) .
and soluble TNF receptors are also upregulated in rheuAbnormal glycosylation of IgG in active RA has been matoid joints (reviewed by Feldmann et al., 1996) . Curreported and may be important because it would favor rent views of the cytokine network in rheumatoid joints, immune complex formation. Other autoantibodies are and probably in other chronic inflammatory sites, thus also present in RA, including those reacting to filaggrin involve two key concepts. First, that TNF␣ is at the apex (Sebbag et al., 1995) .
of a pro-inflammatory cytokine cascade, as illustrated simplistically in Figure 2 . Second, that in a chronic inflammatory site there is also upregulation of multiple
Role of Cytokines in Rheumatoid Arthritis
anti-inflammatory mediators. Hence the rheumatoid syAs cytokines are important mediators of the immune novium can be envisaged as an equilibrium, just tilted and inflammatory systems, establishing their role in autowards the pro-inflammatory side (Figure 3) . A TNF␣ toimmune diseases was of interest, especially in view dependent cytokine cascade is also found in normal of the hypothesis we had proposed in 1983 which linked immune responses, such as in experimental gram negacytokine induced upregulation of antigen presentation tive infections, in which blocking TNF␣ also reduced to the development of autoimmunity. For this purpose IL-1 and IL-6 expression (Fong et al., 1989 et al., 1980) . Both T cell and B cell activation is important biopsies expressed the same broad range of pro-inflamin collagen induced arthritis. Cytokines of both Th1 (IFN␥ matory cytokines, suggesting that synovial cytokine exsecreting) and Th2 cells (IL-4 secreting) are produced, pression in a diseased tissue was prolonged, unlike the and at disease onset a Th1 profile predominates. By transient cytokine production induced by mitogen. This serendipity, another informative model of arthritis was hypothesis was tested by enzymatically dissociating sydeveloped by G. Kollias and colleagues (Keffer et al., novium and culturing the cells without extrinsic stimula-1991). A human TNF␣ transgene was generated in which tion. These cultures produced cytokines such as IL-1 and TNF␣ for a prolonged period of time, indicating that the signals driving cytokine production were present, and so could be studied in vitro. By adding anti-TNF␣ antibodies, it was found that synovial production of other pro-inflammatory cytokines such as IL-1 (Brennan et al., 1989) , GM-CSF, IL-6, and IL-8 was greatly reduced. Blocking IL-1, using the IL-1 receptor antagonist reduced IL-6 and IL-8 production, but not that of TNF␣ (reviewed by Feldmann et al., 1996) . These results indicated that the pro-inflammatory cytokines were linked in a network or cascade. It suggested that blocking benefit because of diminished cell recruitment into joints . was replaced by the stable ␤ globin 3Ј UT, resulting in overexpression of TNF␣. Multiple lines of these mice However, anti-TNF␣ therapy of rheumatoid arthritis is not a cure, and other therapeutic approaches are were found to develop a chronic erosive arthritis. This transgenic model directly demonstrates the concept needed. In collagen induced arthritis in DBA/1 mice, there is marked synergy between anti-TNF antibody that TNF␣ is of importance in the arthritic process, as does the therapeutic benefit of treatment with anti-TNF␣ therapy and therapy targeted at T cells, for example with anti-CD4 antibody, suggesting that synergistic apantibody in the DBA/1 collagen induced arthritis model (Thorbecke et al., 1992; Williams et al., 1994) . Subseproaches targeting these two key aspects of the pathogenesis may be the best approach towards attempting quently it has been found that virtually all animal models of arthritis are ameliorated by anti-TNF␣, including hua cure (Williams et al., 1994) . man-TNF␣ transgenic arthritis, adjuvant arthritis, streptococcal cell-wall arthritis, and antigen induced arthritis Unresolved Issues in rabbits (reviewed by Feldmann et al., 1996) . HistologiThere is much yet to learn about the etiology, pathogencal analysis has demonstrated that anti-TNF␣ therapy, esis, and therapy of rheumatoid arthritis. For example, after disease onset protected the joints from destruction the non-HLA genetic predisposition, which may include induced by the inflammatory process (e.g., Williams et cytokine polymorphism and a tendency to generate relaal., 1994).
tively too many Th1 cells, may yield new clues for therapy. There is debate as to whether the process of joint destruction is directly driven by the inflammatory proImmunotherapy of Rheumatoid Arthritis cess, or whether the basic process of joint destruction, The downregulation of pro-inflammatory cytokines by with proliferation of fibroblasts and other cells is driven anti-TNF␣ antibody in RA joint cultures in vivo and the independently. Certainly in the animal models, antibenefit of anti-TNF␣ in collagen induced arthritis pro-TNF␣ prevents or abrogates joint destruction, sugvided the rationale for clinical trials of anti-TNF␣ antigesting that inflammation and joint destruction are body in longstanding RA patients with active disease.
linked. What drives the production of the excessive The results of multiple clinical trials of anti-TNF␣ anti-TNF␣ in RA joints and why the anti-inflammatory mechabody performed with cA2, a chimeric anti-TNF␣ antinisms cannot fully downregulate its effects are tantalizbody (mouse Fv, human IgG1), have revealed a marked ing questions. What is the major cause of new capillary benefit in all assessable aspects of the disease. There growth (neovascularization) needed to sustain the augwas very rapid improvement, within days, and for an mented cell mass in the synovium? As unravelling the antibody the benefit lasted a long time, ranging from pathogenesis of RA has already led to therapeutic ad-8-26 weeks in the first trial (Elliott et al., 1993) . After vances, it is very likely that answers to the remaining these patients relapsed, retreatment with cA2 on further questions will help generate new treatment approaches. occasions ameliorated disease on each occasion, indicating that the pro-inflammatory cascade remains TNF␣ dependent. The clinical efficacy of anti-TNF␣ has been verified in randomized double-blind placebo-controlled References trials (Elliott et al., 1994) . These results have triggered Arend, W.P., and Dayer, J.-M. (1995) . Inhibition of the production and clinical trials with other anti-TNF␣ reagents, a different effects of interleukin-1 and tumor necrosis factor ␣ in rheumatoid anti-TNF␣ antibody of IgG4 isotype (Rankin et al., 1995), arthritis. Arthritis Rheum. 38, 151-60. and TNF receptor IgG fusion proteins, which have also in terms of cytokine mechanisms. These results emphasize that cytokines may be good therapeutic targets in
